Free Consultation
Patient Portal
GLP-1 medications in a personalized weight loss plan for medical weight loss in Ambler, PA

GLP-1 Medications and their Role in a Personalized Weight Loss Plan

GLP-1 medications have revolutionized the treatment of obesity. For years, people have made lifestyle modifications, tried other medications, and undergone surgical interventions with inconsistent results. Now, we have GLP-1 medications  that can produce meaningful, sustained weight loss and improve overall health in ways that were difficult to achieve with previous options.

Unfortunately, much of the conversation surrounding these medications has been oversimplified. Social media often portrays them as either miracle drugs or evil shortcuts, to the point where some doctors are refusing to prescribe them. The evidence tells a different story.

The reality is that GLP-1 medications are neither miracles nor evil. They are effective tools when used with the right patient, but still only one component of a successful treatment strategy. Lasting success requires much more than a medication. It requires understanding why a person gained weight initially, evaluating for contributing medical conditions, identifying barriers to weight loss, creating realistic goals, preserving muscle mass  with weight loss, managing side effects, monitoring improvements in overall health, and developing strategies to maintain body composition goals after the initial weight loss has been achieved.

I’ve already covered the basics about GLP-1 medications and suggest reading that information first, because in this post, I want to discuss the nuance of using GLP-1 medications. Writing a prescription is the easy part. Everything else is what defines success.

Obesity is a Chronic Illness

Before speaking about GLP-1 medications, it is important to explicitly state that obesity is a chronic illness. It meets all the criteria for chronic illness: it is prolonged, recurrent, does not resolve spontaneously, requires treatment, is multifactorial, produces impairment, progresses, and recurs.1 It is influenced by genetics, hormones, environment, behavior, sleep, stress, medications and several metabolic factors.2 The American Medical Association, World Health Organization, The Obesity Society, American Association of Clinical Endocrinology, the Lancet Commission, and six other organizations recognize obesity as a chronic illness.3-6 Yet some people insist it is not a chronic disease and is simply due to poor self-discipline. Let me be very clear here: obesity is rarely simply due to the lack of willpower.

GLP-1 medications are an effective tool in treating this chronic illness.  The Semaglutide Treatment Effect in People with Obesity (STEP) program involved multiple phase 3 randomized controlled trials that formed the basis for FDA approval of Wegovy for obesity. The STEP trials demonstrated semaglutides unquestionable effectiveness in achieving weight loss in patients with obesity, with and without diabetes, weight regain with discontinuation, and maintained weight loss with continued use.7-11 STEP 3 demonstrated that even greater weight loss occurs when semaglutide is combined with intensive lifestyle modifications.12 The SURMOUNT trials demonstrated similar findings to STEP using tirzepatide.8 The 3-year extension of SURMOUNT-1 revealed tirzepatide reduced progression to type 2 diabetes by 93%.13

For many people, GLP-1 medications opened a door to weight loss they would have never experienced before.

However, medications alone cannot teach people how to eat healthy, preserve muscle mass, improve cardiovascular fitness, or address the underlying factors that contributed to the initial weight gain. Those require a comprehensive treatment plan that includes nutrition,  physical activity, sleep optimization, stress management, and ongoing medical follow-up.

Before Starting GLP-1 Medications: Why Personalization Matters

A common misconception is that a GLP-1 medication is a great option for everyone. Nothing could be further from the truth. Two patients may have the same body composition and require completely different treatment plans.

Before prescribing medication, I want to understand the whole person.

One patient may have struggled with obesity since childhood, while another gained weight rapidly after menopause. One may have type 2 diabetes and fatty liver disease. Another may have untreated obstructive sleep apnea that leaves them exhausted and unable to exercise consistently. Someone else may be taking medications for other medical conditions that cause weight gain such as antidepressants, insulin, and corticosteroids. Additionally, others may have never received evidence-based counseling on nutrition, resistance training, or protein intake despite years of trying to lose weight. Understanding these aspects of a patient, along with nutrition, movement, stress management, and many other factors of the medical and weight loss history, is essential.

Personal and family medical histories are important. GLP-1 medications are contraindicated in some medical conditions and beneficial in others. They have shown benefits in the treatment of type 2 diabetes, cardiovascular disease, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction associated with steatotic liver disease (MASH). While some of these are related to weight loss, the cardiovascular14,15 and kidney16,17 benefits may be independent of weight loss and due to direct effects from the medication. Ongoing research is evaluating their potential role in numerous additional conditions.

It is also important to establish expectations.

GLP-1 medications result in weight loss, but they do not eliminate the need for lifestyle modifications. They do not build muscle. They do not improve cardiovascular fitness. They do nothing to help maintain weight loss if treatment ends. Goals and outcomes help guide every plan. For one patient, success may mean preventing diabetes. For another, it may mean improving mobility to play with their children. Someone else may simply want to reduce knee pain.

Another very important consideration is affordability. There is little value in developing a plan that cannot realistically be maintained because of cost or insurance limitations.

Treating this as a “weight loss” issue, without considering other associated conditions, misses an opportunity to improve overall health. This is not about getting skinny. It is about getting healthy.

Every weight loss program should start with questions, not prescriptions. Only after understanding the whole patient is it possible to determine whether a GLP-1 medication should be part of the treatment plan.

Muscle Loss is Real. Here is How We Minimize It.

Losing muscle mass with GLP-1 medications is a legitimate concern, but it is misunderstood.

Whenever someone loses a significant amount of weight, they lose both fat and lean body mass. However, this is not unique to GLP-1 medications. It occurs with calorie-restricted diets, bariatric surgery, and other medication-assisted weight loss.18,19 The predominant reason this has become part of mainstream discussion is that far more people have lost weight using GLP-1 medications, or are currently using them, compared to other modes of weight loss.18,20  

Losing muscle mass is of great concern because it increases the risk of developing sarcopenia. Sarcopenia is age-related, progressive skeletal muscle loss leading to decreased function. It can negatively impact physical performance and quality of life. It increases vulnerability to falls, fractures, disability, and death, and is now recognized as a major health concern worldwide.21,22 It is estimated that adults lose 5-10% of muscle mass per decade after they reach 50 years of age,23 so losing additional muscle mass during weight loss compounds that risk.

But there are proven strategies for maximizing fat loss while preserving lean mass.

Prioritize Protein

Weight loss, in any form, is the result of a caloric deficit. When food intake decreases, the body must tap into its reserves for energy, most often stored adipose tissue. But the body also requires a steady supply of protein to create enzymes and carry out normal cellular function. When dietary protein intake cannot meet this requirement, the body will resort to breaking down muscle tissue to obtain the necessary amino acids.24 Unlike fat, there is no other dedicated protein storage depot in the body.25 Muscle is it.

This is where adequate protein intake becomes essential, especially for anyone on a GLP-1 medication. Without enough protein, the body does not receive the substrate it needs to function normally and to maintain or build muscle mass.26 And because needs vary from person to person, protein targets are not a one-size-fits-all number. They need to be calculated based on each patient’s long term goals.18 A caloric deficit can exist, but must do so without a nutrition deficit.

Incorporate Resistance Training

Strength training is one of the most effective ways to preserve muscle mass during weight loss.27-30 This allows for continued muscle protein synthesis during periods of caloric restriction, when it would otherwise be compromised.31 The S-LiTE trial demonstrated that combining liraglutide with exercise resulted in a 12% lean mass loss compared to 26% with liraglutide alone.32 The expectation is not for people to turn into bodybuilders. Evidence demonstrates lean mass preservation with 60 to 90 minutes of resistance training per week using resistance bands or weights.29 Twelve minutes of resistance band training Monday through Friday meets that 60-minutes weekly minimum and is far from bodybuilding effort. Supporting resistance training with a high-protein diet further decreases lean mass loss.18

Monitor More Than Body Weight with Body Composition Testing

While a scale can monitor overall weight loss, it fails to track what percentage of that loss is fat mass versus lean mass. Body composition testing breaks down fat and lean mass loss. While there are no clinical studies demonstrating that tracking composition improves muscle preservation, body composition monitoring during GLP-1 therapy is recommended at the expert consensus level.¹⁸  This distinction matters because losing twenty pounds means something very different if that weight loss came from body fat versus muscle mass. Using body composition measurements throughout a weight loss program allows for ongoing monitoring of muscle mass loss, so modifications to preserve lean mass can be made in real time. 

How Long Should Patients Stay on GLP-1 Medications?

Patients often ask me, “Am I going to be on this forever?” And my answer is almost always, “I don’t know.” The reason is that there are no validated tools or biomarkers that predict who will be able to maintain their weight loss after discontinuing medications.

The current evidence demonstrates most people regain weight after stopping the medication.33-35 This should not be surprising. Obesity is a chronic illness. We would not expect someone with hypertension to maintain blood pressure control after discontinuing an antihypertensive medication, so why would we expect it with obesity?

Some patients will require lifelong therapy because obesity is a lifelong disease for them. Potential factors that contribute to rebound weight gain include a higher baseline BMI and greater magnitude of on-treatment weight loss, marked insulin resistance and central adiposity, psychiatric or behavior factors, and socioeconomic factors.36  Others may be able to discontinue medications. There is no single timeline that applies to everyone.

Anecdotally, I have found that individuals who have struggled with obesity most of their lives and have already incorporated significant lifestyle modifications before starting medications are more likely to require long term treatment. These individuals typically regain weight after discontinuing medications. People who have struggled with obesity most of their lives, have not made any lifestyle modifications prior to treatment, incorporate several lifestyle modifications during treatment, and continue those modifications after discontining treatment have a better chance of maintaining their weight loss off medication. Individuals who have not been obese their entire lives, who gained weight over a short period of time such as during pregnancy or following an illness, and who are now struggling to lose that weight tend to require only a short duration of treatment to return to their goal body composition. But I must stress again that this is anecdotal. This is just what I see with my patients in my practice. I have no evidence to support that this is generalizable outside of my practice, or even that it is true.

Duration of treatment is a discussion I have with every single one of my patients when considering initiating a GLP-1 medication because they deserve to know what the long term picture may look like.

What Happens After Reaching Goals of Treatment

Most discussions stop once the goal of treatment is achieved, but this is a very important part of the strategy. As discussed above, some people will be able to discontinue treatment and resume their baseline activities. Others will have established new habits based on the lifestyle modifications learned during treatment and can continue those upon discontinuation of treatment. However, some individuals will require some continued treatment.

There is some emerging data suggesting that dose reduction may help mitigate rebound weight gain after medication discontinuation. A case series of 30 patients demonstrated that those who transitioned from weekly to every-other-week dosing after reaching their treatment goals maintained their treatment outcomes.37 This was just one small study of 30 patients and should be studied in a larger group before it becomes a treatment guideline, but it does suggest a pathway once initial goals are met. For now, the American Diabetes Association recommends therapy at the lowest effective dose for weight loss maintenance, using intermittent therapy, or stopping medication followed by close weight monitoring.38

Cost Consideration is Also Personalized Care

While GLP-1 medications are an excellent option for some individuals, cost is a deciding factor for many. 

Insurance coverage is inconsistent. Some companies will cover the medications for obesity, others require an additional diagnosis such as sleep apnea or diabetes, others will cover only one type of medication, and some companies will cover none of these medications under any circumstance. A medication cannot be considered if a patient cannot afford it. Fortunately, there are options available to help reduce costs. 

LillyDirect offers direct access to certain Eli Lilly medications at transparent pricing for eligible patients. Doctors send the prescription to Eli Lilly’s pharmacy, which charges  patients directly and delivers the medications and supplies to their homes. Novo Nordisk has a similar program. There are also pharmacy discount programs, such as GoodRx, that can reduce out-of-pocket costs for some prescriptions. 

In the US market, patents will start to expire in 2031, and these medications will become more affordable. Until then, financial considerations remain an important part of individualized care. 

Why Seeing a Physician Still Matters in the Era of Online GLP-1 Companies

There are so many online companies offering GLP-1 medications, making it easier to obtain a prescription and at a fraction of the cost. Patients complete questionnaires, upload some photos, meet briefly with a clinician, and a medication arrives at their doorstep.

Improving access to care is a good thing, but that is not what is happening here. Physician-led weight loss focuses on whether medication is appropriate, how it is monitored, and how it fits into a complete health plan. This type of treatment provides access to medications, not a comprehensive program with targeted, individualized care. Almost none of the items I’ve discussed throughout this entire post are addressed by these online programs. Online programs are reasonable if they are being used to acquire the medications while patients seek nutrition counseling, resistance training programs, blood work and vital sign measurements, and body composition monitoring elsewhere. However, that is rarely the case. 

The companies are able to charge lower fees because they utilize medications from compounding pharmacies. Compounded GLP-1 medications cost a fraction of the FDA-regulated medications obtained from commercial pharmacies and pharmaceutical companies. The FDA has issued warnings about compounding pharmacies selling incorrect formulations, contaminated products, or semaglutide “salts” that aren’t the same as the FDA-approved drug.39 In April of 2026, the FDA further clarified the stance on compounding GLP-1 medications, stating that simply adding another component such as B12 does not create a unique compound and is not permitted.40 Obtaining these medications from any source other than the manufacturing pharmaceutical company or a commercial pharmacy that dispenses FDA-regulated medications could result in receiving something less effective or unsafe.

Online programs also rarely manage complications and adverse effects. GLP-1 medications have known adverse effects such as nausea and vomiting. When patients are under the direct care of their physician, prescriptions can be provided to address these symptoms. In some cases, as is true in my office, intravenous fluids are administered when dehydration is a concern.

These programs miss other underlying causes of weight gain, do not invest the time to understand the whole person being treated, and do not manage or monitor complications and adverse effects.

These programs are more focused on getting people skinny, not healthy, and they make a nice profit while doing it.

The Biggest Mistakes I See with GLP-1 Medications

Many of the challenges patients experience are preventable with proper guidance. Common mistakes include:

  • Eating too little protein after appetite decreases.
  • Avoiding resistance training and relying only on walking or cardio.
  • Expecting medications to replace healthy habits.
  • Focusing exclusively on the number on the scale instead of overall health.
  • Stopping medications without a maintenance plan.
  • Comparing their progress with someone else’s journey.

Final Thoughts

Obesity is rarely the result of poor will power. It is a complicated chronic medical condition that occurs because of many different variables, and GLP-1 medications are one of the most significant advances in obesity medicine in decades. I am very frustrated by individuals who shame people for being obese or being on GLP-1 medications.

That being said, these medications are just one piece to a much larger puzzle. Long term success depends on a personalized treatment plan that addresses nutrition, physical activity, muscle preservation, side effect management, ongoing monitoring, and a thoughtful strategy for maintaining results. 

The best plan is not one that simply “makes people skinny” or produces the fastest results. It is the one that helps individuals build healthier habits, improve overall health, and maintain those improvements for years to come.

Disclaimer: Even though I’m a doctor, I’m not your doctor, and reading this blog does not establish a doctor patient relationship. This information is intended for general educational purposes only and should not be taken as personalized medical advice. Always speak with your own healthcare provider before making decisions about your health.

FAQs

GLP-1 medications can support weight loss, but long-term success usually requires more than medication alone. Nutrition, physical activity, muscle preservation, side effect management, ongoing monitoring, and a maintenance plan are also important.

Any significant weight loss can include loss of both fat mass and lean mass. Adequate protein intake, strength training, and body composition monitoring can help reduce unnecessary muscle loss during a weight loss plan.

Physician-led care helps determine whether GLP-1 medications are appropriate, identify medical factors that may affect weight, manage side effects, monitor body composition, and create a personalized plan focused on long-term health rather than weight loss alone.

Who should not take GLP-1 medications? 
GLP-1 medications are not appropriate for everyone. Personal and family medical history, current medications, contraindications, side effects, cost, and individual health goals should be reviewed before deciding whether a GLP-1 medication belongs in a treatment plan. 

References

  1. Sturmberg JP. Multimorbidity and chronic disease: an emergent perspective. Journal of Evaluation in Clinical Practice. 2014;20(4):508-512. doi:https://doi.org/10.1111/jep.12126
  2. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. New England Journal of Medicine. 2017;376(3):254-266. doi:doi:10.1056/NEJMra1514009
  3. Celletti F, Farrar J, De Regil L. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. 2026;335(5):434-438. doi:10.1001/jama.2025.24288
  4. Clinical Issues Committee of the American Society of M, Bariatric S, Carter J, et al. American Society for Metabolic and Bariatric Surgery review of the body mass index. Surgery for Obesity and Related Diseases. 2025;21(3):199-206. doi:10.1016/j.soard.2024.10.038
  5. Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a Disease: The Obesity Society 2018 Position Statement. Obesity. 2019;27(1):7-9. doi:https://doi.org/10.1002/oby.22378
  6. Nadolsky K, Garvey WT, Agarwal M, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update. Endocrine Practice. 2025;31(11):1351-1394. doi:10.1016/j.eprac.2025.07.017
  7. Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity Management in Adults: A Review. JAMA. 2023;330(20):2000-2015. doi:10.1001/jama.2023.19897
  8. Rosen CJ, Ingelfinger JR. GLP-1 Receptor Agonists. New England Journal of Medicine. 2026;394(13):1313-1324. doi:doi:10.1056/NEJMra2500106
  9. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:doi:10.1056/NEJMoa2032183
  10. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. Oct 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4
  11. Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024;332(7):571-584. doi:10.1001/jama.2024.10816
  12. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831
  13. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England Journal of Medicine. 2025;392(10):958-971. doi:10.1056/NEJMoa2410819
  14. Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. Nov 8 2025;406(10516):2257-2268. doi:10.1016/s0140-6736(25)01375-3
  15. Lingvay I, Deanfield J, Kahn SE, et al. Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care. Aug 1 2024;47(8):1360-1369. doi:10.2337/dc24-0764
  16. Chen T-H, Hu E-H, Chen D-Y, et al. GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes. JAMA Network Open. 2025;8(9):e2530952-e2530952. doi:10.1001/jamanetworkopen.2025.30952
  17. Apperloo EM, Cherney DZI, Kuhlman AB, et al. Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6. Nephrol Dial Transplant. Feb 4 2025;40(2):352-359. doi:10.1093/ndt/gfae150
  18. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. The American Journal of Clinical Nutrition. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023
  19. Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026/06/01 2026;28(6):4818-4827. doi:https://doi.org/10.1111/dom.70666
  20. Clapp B, Ponce J, Corbett J, et al. American Society for Metabolic and Bariatric Surgery 2022 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis. May 2024;20(5):425-431. doi:10.1016/j.soard.2024.01.012
  21. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and ageing. 2019;48(1):16-31.
  22. Dent E, Morley J, Cruz-Jentoft A, et al. International clinical practice guidelines for sarcopenia (ICFSR): screening, diagnosis and management. The Journal of nutrition, health and aging. 2018;22(10):1148-1161.
  23. Rodrigues F, Domingos C, Monteiro D, Morouço P. A review on aging, sarcopenia, falls, and resistance training in community-dwelling older adults. International journal of environmental research and public health. 2022;19(2):874.
  24. Olson B, Marks DL, Grossberg AJ. Diverging metabolic programmes and behaviours during states of starvation, protein malnutrition, and cachexia. Journal of Cachexia, Sarcopenia and Muscle. 2020;11(6):1429-1446. doi:https://doi.org/10.1002/jcsm.12630
  25. Cederholm T, Bosaeus I. Malnutrition in Adults. New England Journal of Medicine. 2024;391(2):155-165. doi:doi:10.1056/NEJMra2212159
  26. Pasiakos SM, Margolis LM, Orr JS. Optimized dietary strategies to protect skeletal muscle mass during periods of unavoidable energy deficit. Faseb j. Apr 2015;29(4):1136-42. doi:10.1096/fj.14-266890
  27. Deller M, Weiershaus J, Held S, Brinkmann C. Effects of Calorie Restriction With and Without Strength, Endurance or Mixed Training on Fat-Free and Skeletal Muscle Mass in Overweight or Obese Individuals-A Systematic Review With Pairwise Meta-Analysis and Network Meta-Analysis of Randomized Controlled Studies. Diabetes Obes Metab. May 17 2026;doi:10.1111/dom.70873
  28. Swift DL, Ross LM, Laddu DR, et al. Role of Physical Activity in Obesity Treatment and Cardiometabolic Health: A Scientific Statement From the American Heart Association. Circulation. 0(0)doi:10.1161/CIR.0000000000001441
  29. Mehrtash F, Dushay J, Manson JE. Integrating Diet and Physical Activity When Prescribing GLP-1s—Lifestyle Factors Remain Crucial. JAMA Internal Medicine. 2025;185(9):1151-1152. doi:10.1001/jamainternmed.2025.1794
  30. Lahav Y, Yavetz R, Gepner Y. Resistance training as a key strategy for high-quality weight loss in men and women. Front Endocrinol (Lausanne). 2025;16:1725500. doi:10.3389/fendo.2025.1725500
  31. Hector AJ, McGlory C, Damas F, Mazara N, Baker SK, Phillips SM. Pronounced energy restriction with elevated protein intake results in no change in proteolysis and reductions in skeletal muscle protein synthesis that are mitigated by resistance exercise. Faseb j. Jan 2018;32(1):265-275. doi:10.1096/fj.201700158RR
  32. Lundgren Julie R, Janus C, Jensen Simon BK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine. 2021/05/05 2021;384(18):1719-1730. doi:10.1056/NEJMoa2028198
  33. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. Aug 2022;24(8):1553-1564. doi:10.1111/dom.14725
  34. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Jama. Jan 2 2024;331(1):38-48. doi:10.1001/jama.2023.24945
  35. Tzang CC, Wu PH, Luo CA, et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine. Dec 2025;90:103680. doi:10.1016/j.eclinm.2025.103680
  36. Shah E, AlShiab R, Abdo A, Ozbek L, Covic A, Kanbay M. Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists. Diabetes Obes Metab. Jun 2026;28(6):4546-4558. doi:10.1111/dom.70713
  37. Wong M, Wu A, Garhe PK, Biermann M. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity (Silver Spring). Jun 2026;34 Suppl 1(Suppl 1):112-120. doi:10.1002/oby.70137
  38. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. Jan 1 2026;49(Supplement_1):S166-s182. doi:10.2337/dc26-S008
  39. U.S. Food and Drug Administration. Statement on improving adverse event reporting of compounded drugs to protect patients. https://www.fda.gov/news-events/press-announcements/statement-improving-adverse-event-reporting-compounded-drugs-protect-patients
  40. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration. Updated April 1, 2026. Accessed June 25, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

One comment on “GLP-1 Medications and their Role in a Personalized Weight Loss Plan”

  1. Pingback:

Leave a Reply

Discover more from The Whole Human Health & Wellbeing

Subscribe now to keep reading and get access to the full archive.

Continue reading